RPA2 and ovarian cancer: Additionally, using samples from multiple cohorts of patients with ovarian cancer, we show that HR-proficient, p-RPA2-high HGSCs had significantly better responses to platinum chemotherapy and PARP inhibitors than HR-proficient, p-RPA2-low HGSCs.